Apheresis Market

Market Overview:

The global apheresis market size reached US$ 2.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.3 Billion by 2028, exhibiting a growth rate (CAGR) of 7.55% during 2023-2028.

Apheresis is a procedure of separating donated blood components, such as red blood cells (RBCs), white blood cells (WBCs), platelets, and plasma, to treat various diseases. It assists in treating sickle cell disease wherein red blood cells (RBCs) are shaped abnormally and cannot carry oxygen through the body. It is also employed to remove abnormal white blood cells (WBCs) that thicken the blood and interfere with organ function. In addition, as it aids in treating blood cancers and blood disorders, such as myasthenia gravis and thrombotic thrombocytopenic purpura (TTP), apheresis is widely used in blood collection centers, hospitals, and ambulatory centers across the globe.

Apheresis Market Trends:

The growing demand for apheresis to treat various diseases, such as autoimmune hemolytic anemia, acute disseminated encephalomyelitis, and cardiac neonatal lupus, represents one of the key factors driving the market. Besides this, there is a rise in the utilization of apheresis to collect plasma for treating burnt and trauma patients across the globe. This, along with the burgeoning healthcare industry, is contributing to the growth of the market. Moreover, increasing investments by key market players in research and development (R&D) activities to introduce an enhanced blood purification device that treats severe forms of arteriosclerosis obliterans is positively influencing the market. In addition, the rising demand for source plasma to treat primary immunodeficiency and hemophilia is offering lucrative growth opportunities to industry investors. Apart from this, the growing employment of apheresis as a therapy for various diseases, such as thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, drug toxicities, autoimmune disease, sepsis, and fulminant hepatic failure, is offering a positive market outlook. Additionally, the increasing awareness among the masses about the benefits of apheresis is bolstering the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global apheresis market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on component, product, technology, procedure, application and end user.

Breakup by Component:

• Plasma (Plasmapheresis)
• Platelets (Plateletpheresis)
• Leukocytes (Leukapheresis or Leukopheresis)
• Lymphocytes (Lymphopheresis or Lymphapheresis)
• RBC's (Erythropheresis)
   

Breakup by Product:

• Devices
• Disposables and Reagents
• Software
   

Breakup by Technology:

• Centrifugation
• Membrane Separation
• Selective Adsorption
   

Breakup by Procedure:

• Donor/Automated Apheresis
• Therapeutic Apheresis
   

Breakup by Application:

• Renal Disorders
• Hematological Disorders
• Neurological Disorders
• Autoimmune Disorders
• Others
   

Breakup by End User:

• Blood Centers
• Hospitals
• Others
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Asahi Kasei Medical Co. Ltd. (Asahi Kasei Corporation), B. Braun SE, Charles River Laboratories International Inc., Fresenius Medical Care AG & Co. KGaA, Haemonetics Corporation, Haier Biomedical, Kaneka Corporation, Medica S.p.a., Miltenyi Biotec, Nikkiso Co. Ltd., Sb-Kawasumi Laboratories Inc. (Sumitomo Bakelite Company Limited) and Terumo Bct Inc. (Terumo Corporation).

Report Coverage: